Drug profile · INN
etripamil
CARDAMYST
etripamil (CARDAMYST) is an FDA-listed pharmaceutical active ingredient. Associated with Milestone Pharmaceuticals. Route of administration: nasal. Current US regulatory status: approved.
Drug details — etripamil
- US status
- approved
- Class
- —
- Route
- NASAL
- Patents
- 8
- Programs
- 7
- Data quality
- 0.89
Quick answer
etripamil (CARDAMYST) is an FDA-listed pharmaceutical active ingredient. Associated with Milestone Pharmaceuticals. Route of administration: nasal. Current US regulatory status: approved.
Key facts
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related patents
-
US 12257224
Methods of administration for highly water-soluble salts of a short acting phenylalkylamine calcium channel blocker
granted -
US 10308609
Bicyclic compounds
granted -
US 10251851
Bicyclic analgesic compounds
granted -
US 10117848
Highly water-soluble salts of a short acting phenylalkylamine calcium channel blocker and uses thereof
granted -
US 10010523
Short acting phenylalkylamine calcium channel blockers and uses thereof
granted -
US 10010522
Short acting phenylalkylamine calcium channel blockers and uses thereof
granted -
US 9463179
Short acting phenylalkylamine calcium channel blockers and uses thereof
granted -
US 9227918
Short acting phenylalkylamine calcium channel blockers and uses thereof
granted
Frequently asked questions
What is etripamil?
etripamil (CARDAMYST) is an FDA-listed pharmaceutical active ingredient. Associated with Milestone Pharmaceuticals. Route of administration: nasal. Current US regulatory status: approved.
What is the brand name for etripamil?
CARDAMYST is a marketed brand name for etripamil. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of etripamil?
etripamil has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.